Numan ARR Hits ~$90 M

Numan, a UK-based preventive digital health platform founded in 2018, achieved an annual recurring revenue (ARR) of approximately $90 million by end‑2024, more than doubling its revenue from the previous year. With a cumulative patient base exceeding 650,000 users, Numan has already reached profitability in late 2023 and is poised for ~150 % growth in 2025, projecting revenue to approach $200 million as weight‑loss treatment powered by GLP‑1 prescribing becomes its dominant revenue driver.

Numan offers an integrated, preventive healthcare platform combining telemedicine consultations, prescription medications (including GLP‑1s), diagnostics, AI‑powered health coaching, and behavioral support directly to consumers. Originally focused on men’s health conditions—such as obesity, testosterone deficiency, erectile dysfunction, hair loss, and metabolic wellness—it has now expanded into female health and hormonal care, with enhanced screening and preventive care services. Its proprietary AI health coach provides real‑time personalized guidance, enabling proactive management before chronic conditions escalate.

Backed by a new $60 million Series B extension, Numan’s funding includes $30 million in equity led by Big Pi Ventures, along with $27 million in growth capital from HSBC Innovation Banking, and participation from Endeavor Catalyst, White Star Capital, and Novator Partners. The company has raised around $100 million in equity and $50 million in debt to date. With a Net Promoter Score (NPS) of 68, it is recognized as one of Europe’s most trusted digital health platforms. Numan plans to scale its clinical and AI engineering teams, deepen its AI capabilities for risk prediction and remote monitoring, and enter new markets across Europe and the Middle East, while forging B2B partnerships with employers and insurers to broaden impact and reach.